Display options
Cite
Berenguer D, Sosa L, Alcover M, et al. Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. Pharmaceutics. 2019;11(11)doi: 10.3390/pharmaceutics11110613.
Berenguer, D., Sosa, L., Alcover, M., Sessa, M., Halbaut, L., Guillén, C., Fisa, R., Calpena-Campmany, A. C., & Riera, C. (2019). Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. Pharmaceutics, 11(11), . https://doi.org/10.3390/pharmaceutics11110613
Berenguer, Diana, et al. "Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis." Pharmaceutics vol. 11,11 (2019). doi: https://doi.org/10.3390/pharmaceutics11110613
Berenguer D, Sosa L, Alcover M, Sessa M, Halbaut L, Guillén C, Fisa R, Calpena-Campmany AC, Riera C. Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. Pharmaceutics. 2019 Nov 15;11(11). doi: 10.3390/pharmaceutics11110613. PMID: 31731660; PMCID: PMC6920791.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2019 Nov 15;11(11). doi: 10.3390/pharmaceutics11110613.

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis.

Pharmaceutics

Diana Berenguer, Lilian Sosa, Magdalena Alcover, Marcella Sessa, Lyda Halbaut, Carme Guillén, Roser Fisa, Ana Cristina Calpena-Campmany, Cristina Riera

Affiliations

  1. Department of Biology, Health and Environment, Laboratory of Parasitology, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
  2. Department of Pharmaceutical Technology and Physicochemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.

PMID: 31731660 PMCID: PMC6920791 DOI: 10.3390/pharmaceutics11110613

Abstract

Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimoniate (MA). With the aim of developing an alternative topical treatment for CL, a gel-based formulation with 30% MA was prepared and its physicochemical properties, stability and rheological behavior were studied. The following were assessed: drug release on propylene hydrophilic membranes ex vivo human skin permeation, tolerance in healthy volunteers, cytotoxicity in three cell lines and anti-leishmanial activity against

Keywords: Leishmania infantum; Sepigel 305®; cutaneous leishmaniasis; meglumine antimoniate; topical treatment

References

  1. J Invest Dermatol. 1983 Jun;80(1 Suppl):44s-9s - PubMed
  2. PLoS Negl Trop Dis. 2018 Jul 25;12(7):e0006653 - PubMed
  3. Eur J Pharm Sci. 2018 Mar 30;115:345-351 - PubMed
  4. Clin Infect Dis. 1998 Jan;26(1):56-8 - PubMed
  5. Antimicrob Agents Chemother. 1998 Dec;42(12):3092-6 - PubMed
  6. J Invest Dermatol. 1986 Aug;87(2):284-8 - PubMed
  7. Nanomedicine (Lond). 2015 Jan;10(2):227-40 - PubMed
  8. Int J Pharm Compd. 2019 May-Jun;23(3):200-207 - PubMed
  9. Trans R Soc Trop Med Hyg. 1999 Jan-Feb;93(1):85-90 - PubMed
  10. N Engl J Med. 2013 Feb 7;368(6):524-32 - PubMed
  11. Exp Parasitol. 2019 May;200:30-35 - PubMed
  12. Pharmaceutics. 2019 May 01;11(5):null - PubMed
  13. PLoS Negl Trop Dis. 2019 May 2;13(5):e0007253 - PubMed
  14. Eur J Pharm Sci. 2015 Oct 12;78:140-50 - PubMed
  15. Am J Trop Med Hyg. 2018 May;98(5):1313-1316 - PubMed
  16. Farmaco. 2001 May-Jul;56(5-7):427-31 - PubMed
  17. JAMA. 2013 Nov 27;310(20):2191-4 - PubMed
  18. J Liposome Res. 2010 Mar;20(1):16-23 - PubMed
  19. Acta Trop. 2001 May 25;79(2):179-83 - PubMed
  20. Parasitology. 2018 Apr;145(4):490-496 - PubMed
  21. PLoS One. 2012;7(5):e35671 - PubMed
  22. Skin Res Technol. 2013 Aug;19(3):265-78 - PubMed
  23. Antimicrob Agents Chemother. 2009 Jun;53(6):2259-65 - PubMed
  24. Exp Parasitol. 2000 Jul;95(3):209-14 - PubMed
  25. Curr Opin Investig Drugs. 2002 Apr;3(4):538-44 - PubMed
  26. PLoS Negl Trop Dis. 2013;7(3):e2130 - PubMed
  27. J Am Acad Dermatol. 2015 Dec;73(6):911-26; 927-8 - PubMed
  28. J Pharm Biomed Anal. 2006 May 3;41(2):449-54 - PubMed
  29. Trop Parasitol. 2019 Jul-Dec;9(2):115-123 - PubMed
  30. AAPS PharmSciTech. 2017 Feb;18(2):539-550 - PubMed
  31. J Invest Dermatol. 1989 Aug;93(2):280-6 - PubMed
  32. Drug Deliv. 2018 Nov;25(1):1595-1606 - PubMed
  33. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:456-7 - PubMed
  34. Pharmaceutics. 2019 Jul 03;11(7):null - PubMed
  35. J Invest Dermatol. 1965 May;44:339-44 - PubMed
  36. Infect Dis Poverty. 2018 Jun 18;7(1):67 - PubMed
  37. Exp Parasitol. 2014 Aug;143:5-10 - PubMed

Publication Types